Structural recognition of an ICAM-1 peptide by its receptor on the surface of T cells: conformational studies of cyclo (1, 12)-Pen-Pro-Arg-Gly-Gly-Ser-Val-Leu-Val-Thr-Gly-Cys-OH
- PMID: 10406220
- DOI: 10.1034/j.1399-3011.1999.00080.x
Structural recognition of an ICAM-1 peptide by its receptor on the surface of T cells: conformational studies of cyclo (1, 12)-Pen-Pro-Arg-Gly-Gly-Ser-Val-Leu-Val-Thr-Gly-Cys-OH
Abstract
The purpose of this study is to elucidate the solution conformation of cyclic peptide 1 (cIBR), cyclo (1, 12)-Pen1-Pro2-Arg3-Gly4-Gly5-Ser6-Val7-Leu8-V al9-Thr10-Gly11-Cys12-OH, using NMR, circular dichroism (CD) and molecular dynamics (MD) simulation experiments. cIBR peptide (1), which is derived from the sequence of intercellular adhesion molecule-1 (ICAM-1, CD54), inhibits homotypic T-cell adhesion in vitro. The peptide hinders T-cell adhesion by inhibiting the leukocyte function-associated antigen-1 (LFA-1, CD11a/CD18) interaction with ICAM-1. Furthermore, Molt-3 T cells bind and internalize this peptide via cell surface receptors such as LFA-1. Peptide internalization by the LFA-1 receptor is one possible mechanism of inhibition of T-cell adhesion. The recognition of the peptide by LFA-1 is due to its sequence and conformation; therefore, this study can provide a better understanding for the conformational requirement of peptide-receptor interactions. The solution structure of 1 was determined using NMR, CD and MD simulation in aqueous solution. NMR showed a major and a minor conformer due to the presence of cis/trans isomerization at the X-Pro peptide bond. Because the contribution of the minor conformer is very small, this work is focused only on the major conformer. In solution, the major conformer shows a trans-configuration at the Pen1-Pro2 peptide bond as determined by HMQC NMR. The major conformer shows possible beta-turns at Pro2-Arg3-Gly4-Gly5, Gly5-Ser6-Val7-Leu8, and Val9-Thr10-Gly11-Cys12. The first beta-turn is supported by the ROE connectivities between the NH of Gly4 and the NH of Gly5. The connectivities between the NH of Ser6 and the NH of Val7, followed by the interaction between the amide protons of Val7 and Leu8, support the presence of the second beta-turn. Furthermore, the presence of a beta-turn at Val9-Thr10-Gly11-Cys12 is supported by the NH-NH connectivities between Thr10 and Gly11 and between Gly11 and Cys12. The propensity to form a type I beta-turn structure is also supported by CD spectral analysis. The cIBR peptide (1) shows structural similarity at residues Pro2 to Val7 with the same sequence in the X-ray structure of D1-domain of ICAM-1. The conformation of Pro2 to Val7 in this peptide may be important for its binding selectivity to the LFA-1 receptor.
Similar articles
-
Binding and internalization of an ICAM-1 peptide by the surface receptors of T cells.J Pept Res. 1999 Apr;53(4):414-21. doi: 10.1034/j.1399-3011.1999.00079.x. J Pept Res. 1999. PMID: 10406219
-
Solution structure of a novel T-cell adhesion inhibitor derived from the fragment of ICAM-1 receptor: cyclo(1,8)-Cys-Pro-Arg-Gly-Gly-Ser-Val-Cys.Biopolymers. 2009 Aug;91(8):633-41. doi: 10.1002/bip.21192. Biopolymers. 2009. PMID: 19330816 Free PMC article.
-
Structural and ICAM-1-docking properties of a cyclic peptide from the I-domain of LFA-1: an inhibitor of ICAM-1/LFA- 1-mediated T-cell adhesion.J Biomol Struct Dyn. 2002 Apr;19(5):789-99. doi: 10.1080/07391102.2002.10506785. J Biomol Struct Dyn. 2002. PMID: 11922836
-
Inhibition of homotypic adhesion of T-cells: secondary structure of an ICAM-1-derived cyclic peptide.J Pept Res. 1997 Jun;49(6):517-26. doi: 10.1111/j.1399-3011.1997.tb01159.x. J Pept Res. 1997. PMID: 9266479
-
Solution cis-Proline Conformation of IPCs Inhibitor Aureobasidin A Elucidated via NMR-Based Conformational Analysis.J Nat Prod. 2022 Jun 24;85(6):1449-1458. doi: 10.1021/acs.jnatprod.1c01071. Epub 2022 May 27. J Nat Prod. 2022. PMID: 35622967 Review.
Cited by
-
Binding and internalization of an LFA-1-derived cyclic peptide by ICAM receptors on activated lymphocyte: a potential ligand for drug targeting to ICAM-1-expressing cells.Pharm Res. 2001 Mar;18(3):329-35. doi: 10.1023/a:1011007014510. Pharm Res. 2001. PMID: 11442273
-
Effect of modification of the physicochemical properties of ICAM-1-derived peptides on internalization and intracellular distribution in the human leukemic cell line HL-60.Mol Pharm. 2009 Mar-Apr;6(2):396-406. doi: 10.1021/mp800120t. Mol Pharm. 2009. PMID: 19296614 Free PMC article.
-
Structural modifications of ICAM-1 cyclic peptides to improve the activity to inhibit heterotypic adhesion of T cells.Chem Biol Drug Des. 2008 Jul;72(1):27-33. doi: 10.1111/j.1747-0285.2008.00676.x. Epub 2008 Jun 11. Chem Biol Drug Des. 2008. PMID: 18554252 Free PMC article.
-
Inhibition of the adherence of T-lymphocytes to epithelial cells by a cyclic peptide derived from inserted domain of lymphocyte function-associated antigen-1.Inflammation. 2001 Jun;25(3):203-14. doi: 10.1023/a:1011044616170. Inflammation. 2001. PMID: 11403212
-
Adhesion molecule interactions facilitate human immunodeficiency virus type 1-induced virological synapse formation between T cells.J Virol. 2007 Dec;81(24):13916-21. doi: 10.1128/JVI.01585-07. Epub 2007 Oct 3. J Virol. 2007. PMID: 17913807 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous